Magali Svrcek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Magali Svrcek has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Christelle de la Fouchardière
Medical Oncology Department, Centre Léon Bérard, Lyon, France
2 shared publications - Christophe Louvet
Institut Mutualiste Montsouris, Paris, France
2 shared publications - Christophe Tournigand
Department of Medical Oncology, AP-HP, Henri-Mondor Hospital, Créteil, France
2 shared publications - Jean-Baptiste Bachet
Department of Gastroenterology, Pitié-Salpêtrière Hospital—Sorbonne Université, Paris, France
2 shared publications - Jean-François Fléjou
Service d'anatomie et cytologie pathologiques, hôpital Saint-Antoine, GH HUEP, AP-HP, 184, rue du Faubourg-Saint-Antoine, 75582 Paris cedex 12, France; Faculté de médecine Pierre-et-Marie-Curie, 75571 Paris cedex 12, France
2 shared publications - Jeremie H. Lefevre
Sorbonne Université, Department of Digestive Surgery, AP-HP, Hôpital Saint Antoine, F-75012, Paris, France
2 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 835-848
Direct tumour–adipocyte contact / Stroma AReactive Invasion Front Area ( TAC / SARIFA ) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis
Aims: Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E‐based biomarker in colorectal cancer (CRC). SARIFA positivity is defined by a direct tumour–adipocyte contact (TAC) without intervening stroma or inflammatory infiltrate. We performed a focused evidence synthesis of all published studies and a meta‐analysis to summarize the evidence on the prognostic value of TAC/SARIFA in CRC. Methods and Results: Eligible studies, identified via PubMed (7 May 2026), were observational cohorts reporting multivariable‐adjusted hazard ratios (HRs) for TAC/SARIFA positivity vs negativity, with cancer‐specific survival (CSS) and overall survival (OS) as endpoints. All included studies were retrospective in design. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). Adjusted HRs were pooled using random‐effects meta‐analysis with restricted maximum‐likelihood estimation and Hartung–Knapp confidence intervals. Of 17 records identified, 12 CRC‐focused original publications were included in the qualitative synthesis. Seven cohorts (5,932 patients) contributed CSS and five cohorts (4,545 patients) OS data, drawn from eight independent cohorts across six studies. All studies were rated good quality (NOS 7–9/9). TAC/SARIFA positivity was associated with inferior CSS (pooled HR 1.77, 95% confidence interval [CI] 1.55–2.01) and OS (pooled HR 1.53, 95% CI 1.39–1.68), with no relevant heterogeneity detected. Conclusion: TAC/SARIFA positivity is independently associated with inferior CSS and OS in CRC, warranting prospective validation. We propose TAC as a more descriptive terminology.
- 16 July 2026
- Published by Wiley in Histopathology
- Vol. 89 (5) , 835-848
Open AccessDirect tumour–adipocyte contact / Stroma AReactive Invasion Front Area ( TAC / SARIFA ) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis
Aims: Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E‐based biomarker in colorectal cancer (CRC). SARIFA positivity is defined by a direct tumour–adipocyte contact (TAC) without intervening stroma or inflammatory infiltrate. We performed a focused evidence synthesis of all published studies and a meta‐analysis to summarize the evidence on the prognostic value of TAC/SARIFA in CRC. Methods and Results: Eligible studies, identified via PubMed (7 May 2026), were observational cohorts reporting multivariable‐adjusted hazard ratios (HRs) for TAC/SARIFA positivity vs negativity, with cancer‐specific survival (CSS) and overall survival (OS) as endpoints. All included studies were retrospective in design. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). Adjusted HRs were pooled using random‐effects meta‐analysis with restricted maximum‐likelihood estimation and Hartung–Knapp confidence intervals. Of 17 records identified, 12 CRC‐focused original publications were included in the qualitative synthesis. Seven cohorts (5,932 patients) contributed CSS and five cohorts (4,545 patients) OS data, drawn from eight independent cohorts across six studies. All studies were rated good quality (NOS 7–9/9). TAC/SARIFA positivity was associated with inferior CSS (pooled HR 1.77, 95% confidence interval [CI] 1.55–2.01) and OS (pooled HR 1.53, 95% CI 1.39–1.68), with no relevant heterogeneity detected. Conclusion: TAC/SARIFA positivity is independently associated with inferior CSS and OS in CRC, warranting prospective validation. We propose TAC as a more descriptive terminology.
- Top Cited PapersOpen Access
- 10 January 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (2) , 255-265
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy remains debatable for gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability–high (MSI-H). PATIENTS AND METHODS: NEONIPIGA (ClinicalTrials.gov identifier: NCT04006262 ) phase II study evaluated neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by surgery and adjuvant nivolumab 480 mg once every four weeks (nine injections) in patients with locally advanced resectable dMMR/MSI-H, clinical (c) tumor (T)2-T4 node (N)x metastasis (M)0 gastric/GEJ adenocarcinoma. The primary end point was a pathological complete response (pCR) rate. RESULTS: Between October 2019 and June 2021, 32 patients with dMMR/MSI-H gastric/GEJ adenocarcinoma were enrolled. The median age was 65.5 years (range, 40-80). Clinical stages were cT2-T3N0 (n = 9), cT2-T3N1 (n = 22), and cT3N1M1 (n = 1, wrongly included). With a median follow-up of 14.9 months (95% CI, 10.6 to 17.6), 32 patients received neoadjuvant immunotherapy (27 patients completed all cycles). Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). Twenty-nine patients underwent surgery; three did not have surgery and had complete endoscopic response with tumor-free biopsies and a normal computed tomography scan (two refused surgery and one had metastasis at inclusion). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred). All 29 patients had an R0 resection, and 17 (58.6%; 90% CI, 41.8 to 74.1) had pCR (pathological T0N0). Becker tumor regression grades 1a, 1b, 2, and 3 were observed in 17 patients, three (including two pathological T0N1), two, and seven patients, respectively. Of the 29 patients with surgery, 23 received adjuvant nivolumab. At database lock, no patient had relapse and one died without relapse. CONCLUSION: Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.
- 10 January 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (2) , 255-265
Top Cited PapersOpen AccessNeoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
PURPOSE: In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care. Perioperative chemotherapy remains debatable for gastric/GEJ adenocarcinoma with deficient mismatch repair (dMMR)/microsatellite instability–high (MSI-H). PATIENTS AND METHODS: NEONIPIGA (ClinicalTrials.gov identifier: NCT04006262 ) phase II study evaluated neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by surgery and adjuvant nivolumab 480 mg once every four weeks (nine injections) in patients with locally advanced resectable dMMR/MSI-H, clinical (c) tumor (T)2-T4 node (N)x metastasis (M)0 gastric/GEJ adenocarcinoma. The primary end point was a pathological complete response (pCR) rate. RESULTS: Between October 2019 and June 2021, 32 patients with dMMR/MSI-H gastric/GEJ adenocarcinoma were enrolled. The median age was 65.5 years (range, 40-80). Clinical stages were cT2-T3N0 (n = 9), cT2-T3N1 (n = 22), and cT3N1M1 (n = 1, wrongly included). With a median follow-up of 14.9 months (95% CI, 10.6 to 17.6), 32 patients received neoadjuvant immunotherapy (27 patients completed all cycles). Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). Twenty-nine patients underwent surgery; three did not have surgery and had complete endoscopic response with tumor-free biopsies and a normal computed tomography scan (two refused surgery and one had metastasis at inclusion). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred). All 29 patients had an R0 resection, and 17 (58.6%; 90% CI, 41.8 to 74.1) had pCR (pathological T0N0). Becker tumor regression grades 1a, 1b, 2, and 3 were observed in 17 patients, three (including two pathological T0N1), two, and seven patients, respectively. Of the 29 patients with surgery, 23 received adjuvant nivolumab. At database lock, no patient had relapse and one died without relapse. CONCLUSION: Nivolumab and ipilimumab-based neoadjuvant therapy is feasible and associated with no unexpected toxicity and a high pCR rate in patients with dMMR/MSI-H resectable gastric/GEJ adenocarcinoma.
- Open Access
Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from histology slides of colorectal cancer
Objective: Mismatch Repair Deficiency (dMMR) / Microsatellite Instability (MSI) is a key biomarker in colorectal cancer (CRC). Universal screening of CRC patients for dMMR/MSI status is now recommended, but contributes to increased workload for pathologists and delayed therapeutic decisions. Deep learning has the potential to ease dMMR/MSI testing in clinical practice, yet no comprehensive validation of a clinically approved tool has been conducted. Design: We developed an MSI pre-screening tool, MSIntuit, that uses deep learning to identify MSI status from H&E slides. For training, we used 859 slides from the TCGA database. A blind validation was subsequently performed on an independent dataset of 600 consecutive CRC patients. Each slide was digitised using Phillips-UFS and Ventana-DP200 scanners. Thirty dMMR/MSI slides were used for calibration on each scanner. Prediction was then performed on the remaining 570 patients following an automated quality check step. The inter and intra-scanner reliability was studied to assess MSIntuit’s robustness. Results: MSIntuit reached a sensitivity and specificity of 97% (95% CI: 93-100%) / 46% (42-50%) on DP200 and of 95% (90-98%) / 47% (43-51%) on UFS scanner. MSIntuit reached excellent agreement on the two scanners (Cohen’s κ: 0.82) and was repeatable across multiple rescanning of the same slide (Fleiss’ κ: 0.82). Conclusion: We performed a successful blind validation of the first clinically approved AI-based tool for MSI detection from H&E slides. MSIntuit reaches sensitivity comparable to gold standard methods (92-95%) while ruling out almost half of the non-MSI population, paving the way for its use in clinical practice.
Open AccessBlind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from histology slides of colorectal cancer
Objective: Mismatch Repair Deficiency (dMMR) / Microsatellite Instability (MSI) is a key biomarker in colorectal cancer (CRC). Universal screening of CRC patients for dMMR/MSI status is now recommended, but contributes to increased workload for pathologists and delayed therapeutic decisions. Deep learning has the potential to ease dMMR/MSI testing in clinical practice, yet no comprehensive validation of a clinically approved tool has been conducted. Design: We developed an MSI pre-screening tool, MSIntuit, that uses deep learning to identify MSI status from H&E slides. For training, we used 859 slides from the TCGA database. A blind validation was subsequently performed on an independent dataset of 600 consecutive CRC patients. Each slide was digitised using Phillips-UFS and Ventana-DP200 scanners. Thirty dMMR/MSI slides were used for calibration on each scanner. Prediction was then performed on the remaining 570 patients following an automated quality check step. The inter and intra-scanner reliability was studied to assess MSIntuit’s robustness. Results: MSIntuit reached a sensitivity and specificity of 97% (95% CI: 93-100%) / 46% (42-50%) on DP200 and of 95% (90-98%) / 47% (43-51%) on UFS scanner. MSIntuit reached excellent agreement on the two scanners (Cohen’s κ: 0.82) and was repeatable across multiple rescanning of the same slide (Fleiss’ κ: 0.82). Conclusion: We performed a successful blind validation of the first clinically approved AI-based tool for MSI detection from H&E slides. MSIntuit reaches sensitivity comparable to gold standard methods (92-95%) while ruling out almost half of the non-MSI population, paving the way for its use in clinical practice.
- Open Access
- 25 September 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (2) , 282-288
SupportiNg operAtive Photographic documentation in ileocolonic CROHN's disease surgery: The SNAPCROHN study
Background There are reported variations in the intraoperative management of Crohn's disease. This consensus statement aimed to develop a standardised protocol for photographic documentation of intraoperative findings and critical procedural steps in ileocolonic Crohn's disease surgery. Methods Colorectal surgeons with a specialist interest in minimally invasive surgery and inflammatory bowel disease were invited as committee members to develop a survey on the use of photo-documentation in Crohn's disease surgery. A 15 item survey was developed on ethical considerations and applications of photo-documentation in audit and quality control, research, and training. Results There was strong agreement on the potential application of intraoperative photo-documentation in Crohn's disease for training, research, quality control and tertiary referrals. Reviewers agreed that intraoperative staging required photo-documentation of strictures, skip lesions, perforations, fat wrapping and mesenteric disease. The necessary steps to be photo-documented were very specific to Crohn's disease surgery, such as views of anastomosis and strictureplasties, and extent of resection(s). Conclusions Our consensus statement identified several items for appropriate intraoperative photo-documentation in Crohn's disease surgery, to be used as an adjunct to accurate annotation of intraoperative findings and procedures.
- 25 September 2022
- Published by Wiley in Colorectal Disease
- Vol. 25 (2) , 282-288
Open AccessSupportiNg operAtive Photographic documentation in ileocolonic CROHN's disease surgery: The SNAPCROHN study
Background There are reported variations in the intraoperative management of Crohn's disease. This consensus statement aimed to develop a standardised protocol for photographic documentation of intraoperative findings and critical procedural steps in ileocolonic Crohn's disease surgery. Methods Colorectal surgeons with a specialist interest in minimally invasive surgery and inflammatory bowel disease were invited as committee members to develop a survey on the use of photo-documentation in Crohn's disease surgery. A 15 item survey was developed on ethical considerations and applications of photo-documentation in audit and quality control, research, and training. Results There was strong agreement on the potential application of intraoperative photo-documentation in Crohn's disease for training, research, quality control and tertiary referrals. Reviewers agreed that intraoperative staging required photo-documentation of strictures, skip lesions, perforations, fat wrapping and mesenteric disease. The necessary steps to be photo-documented were very specific to Crohn's disease surgery, such as views of anastomosis and strictureplasties, and extent of resection(s). Conclusions Our consensus statement identified several items for appropriate intraoperative photo-documentation in Crohn's disease surgery, to be used as an adjunct to accurate annotation of intraoperative findings and procedures.
- Open Access
- 1 September 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 118, 190
Erratum to ‘Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)’ [Eur J Cancer 107 (January 2019) 46–52]
- 1 September 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 118, 190
Open AccessErratum to ‘Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)’ [Eur J Cancer 107 (January 2019) 46–52]
- 25 September 2011
- Published by Springer Nature in Nature Medicine
- Vol. 17 (10) , 1283-1289
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110ΔE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC.
- 25 September 2011
- Published by Springer Nature in Nature Medicine
- Vol. 17 (10) , 1283-1289
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110ΔE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110ΔE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC.
- Open Access
- 1 January 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (1) , 232-240
Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer
Inflammatory bowel disease (IBD) exposes patients to an increased risk of colorectal cancer (i-CRC) and differences between i-CRC and sporadic colorectal cancer (s-CRC) pathogenesis were reported. In s-CRC, studies indicate abnormalities in the tumor-suppressor gene Cdx2. This study compared CDX2, β-catenin, and TP53 expression in i-CRC, s-CRC, noncancer IBD, and normal control colonic mucosa. Expression was investigated by immunohistochemistry in 10 normal, 20 s-CRC, 11 noncancer colonic IBD and 30 i-CRC samples, and in four samples of Crohn's disease (CD)-associated small bowel adenocarcinoma (i-SBA). In normal and noncancer IBD samples, CDX2 was confined to the colonocytes nuclei. CDX2 expression was normal in 90% of i-CRC, regardless of tumor differentiation or inflammation intensity. By contrast, CDX2 expression was altered in 45% s-CRC, particularly at the front of invasion in undifferentiated tumors. β-Catenin was restricted to cell membrane in all controls, in 91% noncancer IBD, and in 84% i-CRC samples, whereas 35% s-CRC showed cytoplasmic redistribution and exclusive nuclear staining at the front of invasion. TP53 was strongly and homogeneously expressed in i-CRC nuclei compared to normal control or s-CRC, and increases with inflammation intensity. Nested or diffuse TP53 was found in 81.8% of noncancer IBD samples with a higher proportion of TP53-expressing cells in the most inflamed samples. CDX2, β-catenin, and TP53 expression in CD-associated SBA appears similar to that of i-CRC. Neither Cdx2 nor β-catenin alterations are prominent features of i-CRC. In i-CRC and CD-associated SBA, carcinogenesis is associated early with p53 mutations and to inflammation intensity.
- 1 January 2011
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (1) , 232-240
Open AccessImmunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer
Inflammatory bowel disease (IBD) exposes patients to an increased risk of colorectal cancer (i-CRC) and differences between i-CRC and sporadic colorectal cancer (s-CRC) pathogenesis were reported. In s-CRC, studies indicate abnormalities in the tumor-suppressor gene Cdx2. This study compared CDX2, β-catenin, and TP53 expression in i-CRC, s-CRC, noncancer IBD, and normal control colonic mucosa. Expression was investigated by immunohistochemistry in 10 normal, 20 s-CRC, 11 noncancer colonic IBD and 30 i-CRC samples, and in four samples of Crohn's disease (CD)-associated small bowel adenocarcinoma (i-SBA). In normal and noncancer IBD samples, CDX2 was confined to the colonocytes nuclei. CDX2 expression was normal in 90% of i-CRC, regardless of tumor differentiation or inflammation intensity. By contrast, CDX2 expression was altered in 45% s-CRC, particularly at the front of invasion in undifferentiated tumors. β-Catenin was restricted to cell membrane in all controls, in 91% noncancer IBD, and in 84% i-CRC samples, whereas 35% s-CRC showed cytoplasmic redistribution and exclusive nuclear staining at the front of invasion. TP53 was strongly and homogeneously expressed in i-CRC nuclei compared to normal control or s-CRC, and increases with inflammation intensity. Nested or diffuse TP53 was found in 81.8% of noncancer IBD samples with a higher proportion of TP53-expressing cells in the most inflamed samples. CDX2, β-catenin, and TP53 expression in CD-associated SBA appears similar to that of i-CRC. Neither Cdx2 nor β-catenin alterations are prominent features of i-CRC. In i-CRC and CD-associated SBA, carcinogenesis is associated early with p53 mutations and to inflammation intensity.